Nuvalent, Inc. (NUVL)

$16.77

+0.27 (+1.64%)
Rating:
Recommendation:
-
Symbol NUVL
Price $16.77
Beta 0.000
Volume Avg. 0.15M
Market Cap 811.888M
Shares () -
52 Week Range 7.09-31.43
1y Target Est -
DCF Unlevered NUVL DCF ->
DCF Levered NUVL LDCF ->
ROE -25.55% Sell
ROA -26.91% Sell
Operating Margin -
Debt / Equity 3.97% Neutral
P/E -
P/B 3.20 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NUVL news


Healthcare
Biotechnology
NASDAQ Global Select

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.